Guest Dr. Vedang Murthy and host Davide Soldato discuss JCO article, "Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer" and delve into trial design, results, clinical implications, and future directions in bladder cancer treatment.

LINK TO FULL TRANSCRIPT

In this episode of JCO Article Insights, host Ash Gurumurthi summarizes the article "Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma," by Mehta-Shah and colleagues.

LINK TO FULL TRANSCRIPT

Guests Dr. Elise Park, Dr. Jamie Ostrov and host Dr. Davide Soldato discuss JCO article "Virtual Sustained Tobacco Treatment for Cancer Patients: A Randomized Controlled Trial (ECOG-ACRIN: EAQ171CD) within the NCI Community Oncology Research Program (NCORP)" and their groundbreaking trial on virtual tobacco cessation treatment for cancer patients in community settings.

LINK TO FULL TRANSCRIPT

Guests Akash Kulgod and Dr. Sanjeev Kulgod and host Dr. Davide Soldato discuss JCO article, "Canine Olfaction Combined with Bayesian Modeling for Multi Cancer Detection from Breath Samples, a Phase 2 Study in India" and the innovative breath-based canine olfaction for multi-cancer detection in low-resource settings, the Bayesian modeling integration, and future prospects for scalable, non-invasive cancer screening methods.

LINK TO FULL TRANSCRIPT

JCO Editorial Fellow Dr. Ash Gurumurthi and JCO Associate Editor Dr. Grant McArthur discuss the ASCO 2026 Simultaneous Publication paper "Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 Study."

LINK TO FULL TRANSCRIPT

JCO Podcast host Dr. Davide Soldato and JCO Associate Editor Dr. Dr. Eileen M. O'Reilly discuss the ASCO 2026 Simultaneous Publication paper "Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial."

LINK TO FULL TRANSCRIPT

JCO Editorial Fellow Dr. Yuvanesh Vedaraju and JCO Associate Editor Dr. Kathy Miller discuss the ASCO 2026 Simultaneous Publication paper "Low-Dose Tamoxifen in Non-Invasive Breast Neoplasia: Long-Term Results from an Individual Participant Data Pooled Analysis."

LINK TO FULL TRANSCRIPT

JCO Editorial Fellow Dr. Jake New and JCO Associate Editor Dr. Umang Swami discuss the ASCO 2026 Simultaneous Publication paper "Neoadjuvant Sacituzumab Govitecan in Patients with Muscle-Invasive Bladder Cancer: Primary Results of SURE-01 Trial."

LINK TO FULL TRANSCRIPT

JCO Editorial Fellow Dr. Jake New and JCO Associate Editor Dr. Andrea Necchi discuss the ASCO 2026 Simultaneous Publication paper "Addition of Intravesical Recombinant BCG to Perioperative Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single Arm Phase 2 Trial SAKK 06/19."

LINK TO FULL TRANSCRIPT

Guest Dr. Glenwood Goss and host Dr. Davide Soldato discuss JCO article, "Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer" and the implications of minimal residual disease, results regarding the efficacy of immunotherapy in the adjuvant setting, and the evolving strategies for patient care in lung cancer treatment.

LINK TO FULL TRANSCRIPT